Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients A Hellenic Cooperative Oncology Group Study

Papadimitriou, Christos; Fountzilas, George; Aravantinos, G.; Kalofonos, C.; Moulopoulos, Lia A.; Briassoulis, Evangelos; Gika, Dimitra; Dimopoulos, Meletios Α.

doi:10.1016/j.ygyno.2003.09.021

Cited by 35 publications

(21 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We demonstrated greater benefit with the combination regimen of gemcitabine/ platinum than gemcitabine alone: higher RR (60 vs 6%, p=0.028) and longer PFS (8 months vs 3 months, p=0.007). This was consistent with previous reports showing high or better RR and improved survival of gemcitabine in combination with platinum (Papadimitriou et al, 2004;Pfisterer et al, 2006). Pfisterer et al randomized 356 patients with platinum-sensitive disease to have combination regimen (carboplatin and gemcitabine) with single regimen (carboplatin).…”

Section: Discussionsupporting

confidence: 91%

“…Treatment outcomes were significantly improved in the combination arm in terms of RR (47% vs 31%) and PFS (9 months vs 6 months) (Pfisterer et al, 2006). Another phase II prospective study by Papadimitriou et al also showed high RR of 41% and PFS of 9 months with combined treatment (Papadimitriou et al, 2004).We were humbly aware that the number in this particular group of patients was very small (five patients) and might have exaggerated the RR to much higher than those found in the two previous studies (60% compared to 47% or 41%).…”

Section: Discussionmentioning

confidence: 91%

“…Third was the regimen of gemcitabine. Some studies found RRs of 6-29% from single agent (Shapiro et al, 1996;Friedlander et al, 1998;D'Agostino et al, 2003;Markman et al, 2003;Mutch et al, 2007;Ferrandina et al, 2008;Watanabe et al, 2008;Suprasert et al, 2012;Yoshino et al, 2012) while others could demonstrate RRs of 13-70% from gemcitabine in combination with platinum or other agents (Greggi et al, 2001;Sehouli et al, 2002;Nagourney et al, 2003;Rose et al, 2003;Garcia et al, 2004;Papadimitriou et al, 2004;Ferrandina et al, 2005;Brewer et al, 2006;Pfisterer et al, 2006;Poole et al, 2006;Bozas et al, 2007). Another reason which might be under-recognized was the setting when gemcitabine was used or numbers of prior chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…Gemcitabine was also tested with other drugs as a combination regimen e.g. cisplatin (Nagourney et al, 2003;Rose et al, 2003;Brewer et al, 2006;Bozas et al, 2007) or carboplatin (Papadimitriou et al, 2004;Pfisterer et al, 2006), PLD (Ferrandina et al, 2005), paclitaxel (Garcia et al, 2004;Poole et al, 2006), topotecan (Greggi et al, 2001;Sehouli et al, 2002), producing high RRs of 13-70% (Greggi et al, 2001;Sehouli et al, 2002;Nagourney et al, 2003;Rose et al, 2003;Garcia et al, 2004;Papadimitriou et al, 2004;Ferrandina et al, 2005;Brewer et al, 2006;Pfisterer et al, 2006;Poole et al, 2006;Bozas et al, 2007).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Treatment Outcomes of Gemcitabine in Refractory or Recurrent Epithelial Ovarian Cancer Patients

Chanpanitkitchot

Tangjitgamol²,

Khunnarong³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: To study the response rate (RR), progression-free survival (PFS) and toxicity profiles of recurrent epithelial ovarian cancer (EOC) patients treated with gemcitabine. Materials and Methods: Recurrent EOC patients who were treated with gemcitabine between January 2000 and December 2013 at the Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital were identified and medical records were reviewed. Clinico-pathological features including data of gemcitabine treatment, response and toxicity were collected. Results: We identified 43 EOC patients who had gemcitabine treatment. All except one patient who did not receive any adjuvant treatment, had received platinum-based chemotherapy. Among these 42 patients, 31.0% had refractory cancer to first-line chemotherapy while 69.0% had recurrence with 48.8% being platinumsensitive. The total cycles of gemcitabine used were 203 (median 4, range 2-9 cycles). Overall RR was 11.6%: 19% in platinum-sensitive vs 4.5% in platinum-resistant groups (p=0.158) and 42.9% in the patients having gemcitabine together with platinum vs 5.6% using gemcitabine alone (P=0.024). Median PFS was 3.6 months (95% confidence interval [CI], 2.73-4.49 months): 8.1 months (95% CI, 2.73-4.49 months) in combination regimen vs 3.2 months (95% CI, 2.01-4.42 months) in single regimen (p=0.077) and 8.1 months (95% CI, 4.73-11.48 months) with the gemcitabine combination vs 2.7 months (95% CI, 1.98-3.38 months) by single gemcitabine in platinum sensitive patients (P=0.007). Common toxicities were hematologic which were well tolerated and manageable. Conclusions: Gemcitabine has modest activity in pre-treated EOC. A combination regimen had higher activity than single agent in platinum sensitive patients with a significant improvement in RR and PFS.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Treatment Outcomes of Gemcitabine in Refractory or Recurrent Epithelial Ovarian Cancer Patients

Chanpanitkitchot

Tangjitgamol²,

Khunnarong³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…50% of patients experience relapse by 36 months (5-year survival <20%). In relapses that occur more than 6 months after completion of prior platinum based chemotherapy (platinum-sensitive disease), re-treatment with platinum is associated with response in 40-72% [4][5][6]. A novel albumin-bound paclitaxel (nab-paclitaxel) offers advantages over standardformula paclitaxel or docetaxel administration, may be an effective strategy as monotherapy in patients with platinum/taxane-sensitive disease [7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Nab-Paclitaxel in Recurrent Ovarian Cancer: An Institution Based Retrospective Study

Singh¹,

Pankaj²,

Kota³

et al. 2015

JCR

View full text Add to dashboard Cite

Abstract:Introduction: Nab-paclitaxel is a novel cremophor free nanoparticle of albumin-stabilized paclitaxel. We evaluated the efficacy and toxicity of the nab-paclitaxel in recurrent ovarian cancer patients. Methods: 17 patients of recurrent epithelial ovarian cancer with platinum and taxane resistance defined by persistent or progressive disease following recurrence within six months of treatment completion and measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) or elevated CA-125 (≥ 70 U/ mL) in patients without measurable disease were included in trial. Patients were treated with nab-paclitaxel for six cycles or until disease progression. Results: Median age of patients was 62 years; 76% of patients had stage IIIC or IV disease, 82% had Eastern Cooperative Oncology Group performance status of 0, and 88% had prior surgery. For assessable patients, the objective response rate (ORR) was 58% (6 complete responses [CR] and 4 partial responses [PR] among 17 assessable patients). In patients evaluated with RECIST only, the ORR was 44.4% (one CR and three PR of 9 patients). In patients with only elevated CA-125, ORR was 75% (5 CRs and 1 PRs of 8 patients). Median time to response was 1.3 months (range 0.5 to 4.8 months). Estimated median progression-free survival was 8.5 months. The most frequent grade 3 to 4 treatment-related toxicities were neutropenia (35%) and neuropathy (11%). Conclusion: Nab-paclitaxel as a single agent in patients with recurrent epithelial ovarian cancer seems to be well tolerated and effective in patients who are previously treated with paclitaxel or platins.

show abstract

Clinical Activity of Gemcitabine as a Single Agent and in Combination

Kroep

Peters

Nagourney

Cancer Drug Discovery and Development

View full text Add to dashboard Cite

Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients A Hellenic Cooperative Oncology Group Study

Cited by 35 publications

References 34 publications

Treatment Outcomes of Gemcitabine in Refractory or Recurrent Epithelial Ovarian Cancer Patients

Treatment Outcomes of Gemcitabine in Refractory or Recurrent Epithelial Ovarian Cancer Patients

Nab-Paclitaxel in Recurrent Ovarian Cancer: An Institution Based Retrospective Study

Clinical Activity of Gemcitabine as a Single Agent and in Combination

Contact Info

Product

Resources

About